EXAS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXAS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Exact Sciences's Marketable Securities for the quarter that ended in Sep. 2024 was $432 Mil.
Exact Sciences's annual Marketable Securities declined from Dec. 2021 ($715 Mil) to Dec. 2022 ($390 Mil) and declined from Dec. 2022 ($390 Mil) to Dec. 2023 ($172 Mil).
The historical data trend for Exact Sciences's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Marketable Securities | Get a 7-Day Free Trial | 146.40 | 348.70 | 715.01 | 389.56 | 172.27 |
Exact Sciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Marketable Securities | Get a 7-Day Free Trial | 139.79 | 172.27 | 304.61 | 416.60 | 432.30 |
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Exact Sciences (NAS:EXAS) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Thank you for viewing the detailed overview of Exact Sciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin T Conroy | director, officer: Vice President | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Brian Baranick | officer: Gen. Mgr., Precision Oncology | 441 CHARMANY DRIVE, MADISON WI 53719 |
Jacob A Orville | officer: General Manager, New Ventures | 5505 ENDEAVOR LANE, MADISON WI 53719 |
James Herriott | officer: General Counsel | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Sarah Condella | officer: SVP, Human Resources | 441 CHARMANY DRIVE, MADISON WI 53719 |
D Scott Coward | officer: SVP and General Counsel | 441 CHARMANY DRIVE, MADISON WI 53719 |
Jeffrey Thomas Elliott | officer: Chief Financial Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Everett Cunningham | officer: Chief Commercial Officer | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Daniel J Levangie | director | 85 SWANSON ROAD, BOXBOROUGH MA 01719 |
James Edward Doyle | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Katherine S Zanotti | director | 431 E 9TH STREET, HINSDALE IL 60521 |
Paul J Clancy | director | C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Graham Peter Lidgard | officer: SVP, Chief Scientific Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael S Wyzga | director | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 09-16-2024
By GuruFocus Research • 09-11-2024
By GuruFocus News • 11-04-2024
By Business Wire • 10-08-2024
By Business Wire • 08-28-2024
By GuruFocus News • 11-06-2024
By Business Wire • 11-25-2024
By GuruFocus News • 10-09-2024
By GuruFocus News • 12-04-2024
By GuruFocus Research • 09-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.